CRP and adiponectin and its oligomers in the metabolic syndrome : Evaluation of new laboratory-based biomarkers

American Journal of Clinical Pathology

Volumn 129, Issue 5, 2008, Pages 815-822

  Devaraj, Sridevi ^a   Swarbrick, Michael M ^b   Singh, Uma ^a   Adams Huet, Beverley ^c   Havel, Peter J ^b   Jialal, Ishwarla ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adiponectin; Biomarker; C reactive protein; Metabolic syndrome

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; OLIGOMER;

ADULT; ARTICLE; BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; REFERENCE VALUE; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADIPONECTIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 44849110323     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/RN84K51B2JJY1Y0B     Document Type: Article

References (40)

1. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Ann Rev Nutr. 2005;25:391-406.
2. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am. 2004;33:431-453.
3. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-2825.
4. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107:391-397.
5. Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110:380-385.
6. Aguilar D, Fisher MR, O'Connor CM, et al; Investigators in the Weekly Intervention with Zithromax for Atherosclerosis and Its Related Disorder Study. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. Am Heart J. 2006;152:298-304.
7. Linnemann B, Voigt W, Nobel W, et al. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes. 2006;114:127-134.
8. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
9. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986-1991.
10. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-978.
11. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53(suppl 1):S143-S151.
12. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
13. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-1599.
14. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-89.
15. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8:731-737.
16. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277:25863-25866.
17. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57-58.
18. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-1737.
19. Wannamethee SG, Tchernova J, Whincup P, et al. Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance - related than to coronary heart disease risk - related parameters. Int J Obes (Lond). 2007;31:1089-1098.
20. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671-674.
21. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278:40352-40363.
22. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152-12162.
23. Swarbrick MM, Austrheim-Smith IT, Stanhope KL, et al. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia. 2006;49:2552-2558.
24. Bobbert T, Rochlitz H, Wegewitz U, et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes. 2005;54:2712-2719.
25. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
26. Devaraj S, O'Keefe G, Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab. 2005;90:4549-4554.
27. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.
28. Ebinuma H, Miyazaki O, Yago H, et al. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta. 2006;372:47-53.
29. D'Alessandris C, Lauro R, Presta I, et al. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser(307) and Ser(612) in L6 myocytes, thereby impairing the insulin signaling pathway that promotes glucose transport. Diabetologia. 2007;50:840-849.
30. Basu R, Pajvani UB, Rizza RA, et al. Selective downregulation of the high molecular weight form (HMW) of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from non-diabetic subjects. Diabetes. 2007;56:2174-2177.
31. Yuan G, Chen X, Ma Q, et al. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol. 2007;194:275-281.
32. Fisher FF, Trujillo ME, Hanif W, et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia. 2005;48:1084-1087.
33. Polak J, Kovacova Z, Jacek M, et al. An increase in plasma adiponectin multimeric complexes follows hypocaloric dietinduced weight loss in obese and overweight pre-menopausal women. Clin Sci (Lond). 2007;112:557-565.
34. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935.
35. Lara-Castro C, Luo N, Wallace P, et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006;55:249-259.
36. Matsubara M, Namioka K, Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol. 2003;148:657-662.
37. Tsao TS, Tomas E, Murrey HE, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J Biol Chem. 2003;278:50810-50817.
38. Abbasi F, Chang SA, Chu JW, et al. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol. 2006;290:R139-R144.
39. Abbasi F, Lamendola C, McLaughlin T, et al. Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. Metabolism. 2004;53:280-283.
40. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006;29:1357-1362.